This study was intended to investigate into the incidence rates of deep vein thrombosis (DVT) in patients who used prophylactic antithrombotic medications after total knee arthroplasty (TKA), and to compare clinical r...This study was intended to investigate into the incidence rates of deep vein thrombosis (DVT) in patients who used prophylactic antithrombotic medications after total knee arthroplasty (TKA), and to compare clinical results in groups treated with Rivaroxaban versus Dalteparin sodium as prophylactic antithrombotic medications. This prospective study was performed in 300 patients who underwent TKA between November 2011 and December 2012. The prophylactic therapy was given to 150 patients in Rivaroxaban group and Dalteparin sodium group, respectively. In addition, intermittent compression pump and stocking were used in all the groups immediately after TKA. In order to determine the incidence of DVT, color Doppler ultrasonography, D-dimer, and clinical symptom examination were conducted. There were 17 cases (11.3%) of DVT in Rivaroxaban group and 18 cases (12.0%) of DVT in Dalteparin sodium group after TKA, and no significant difference was seen between both groups. Between patients with DVT and those without DVT after TKA at 4 days in both groups, there was a significant difference in the swelling indices. Moreover, a significant difference was observed in the evaluation of bruise. The early signs of DVT after TKA are unknown, however, some initial clinical signs such as swelling have been observed. After using the said prophylactic drugs, the lower incidence of DVT was seen, and there was no difference between the types of drugs. Pharmacological therapy (either Rivaroxaban or Dalteparin sodium) after TKA is considered effective for DVT prevention. There is also a need to consider constant monitoring of clinical symptoms.展开更多
Objective To prospectively evaluate the safety and therapeutic efficacy ofdalteparin in patients with high risk non-ST- elevation acute coronary syndromes （ACS） during percutaneous coronary intervention （PCI）. Met...Objective To prospectively evaluate the safety and therapeutic efficacy ofdalteparin in patients with high risk non-ST- elevation acute coronary syndromes （ACS） during percutaneous coronary intervention （PCI）. Methods A total of 175 patients with high risk non-ST-elevation ACS were randomly assigned to 2 groups [dalteparin group and unfractionated heparin （UFH） group]. The patients in dalteparin group were given dalteparin at a dose of 5,000U subcutaneously soon after diagnosis and then an additional 60U/ kg intravenous bolus ofdalteparin before emergent PCI. Vascular access sheaths were removed immediately after PCI or coronary artery angiography; the patients in UFH group were given UFH intravenously at a dose of 25mg just before PCI and an additional 65mg bolus was administered if angiographic findings showed that the patients were suitable for percutaneous transluminal coronary angioplasty （PTCA）. Sheaths were removed at 4-6 hours after PCI; Results Eighty-three patients in dalteparin group underwent PCI while 82 patients in UFH group underwent PCI; anti-Xa activities of 52 patients in daltepafin group were measured. The average anti-Xa activity was （0. 83± 0.26） U/ml at 15 minutes after intravenous injection of dalteparin and anti-Xa〉0.SU/ml was obtained in 96.1% of the patients; hematomas at puncture sites were significantly fewer in dalteparin group as compared with UFH group （2.3% vs 9.2%, P 〈 0.05）; none of the patients in 2 groups suffered major bleeding events. No death, acute arterial reocclusion or emergent revascularization events occurred at 30 days after PCI. Conclusions Our study demonstrated that early subcutaneous injection ofdalteparin at a dose 5,000U after diagnosis and an additional 60U/kg intravenous bolus ofdalteparin before PCI is safe and efficacious for patients with high risk non-ST-elevation ACS undergoing emergent PCI.展开更多
Objective:To investigate the therapeutic effect of trans-tarsal sinus approach surgery combined with dalteparin sodium and furosemide in the treatment of heel bone fracture.Methods:A hundred patients with heel bone fr...Objective:To investigate the therapeutic effect of trans-tarsal sinus approach surgery combined with dalteparin sodium and furosemide in the treatment of heel bone fracture.Methods:A hundred patients with heel bone fracture who were hospitalized from August 2023 to January 2025 were selected and randomly divided into two groups of 50 cases each.The control group was operated by purely trans-tarsal sinus approach,and the observation group added dalteparin sodium and furosemide on this basis.Postoperative limb swelling,pain,coagulation and inflammation indexes,fracture healing time,foot function and complications were compared between the two groups.Results:In the observation group,postoperative limb swelling subsided faster,pain score was lower,coagulation and inflammation indexes improved more significantly,fracture healing time was shorter,foot function recovery was better,and complication rate was lower,P<0.05.Conclusion:The treatment of heel fracture by trans-tarsal sinus approach combined with sodium heparin and furosemide can significantly accelerate the patient’s recovery and reduce the occurrence of complications,which has high clinical application value.展开更多
目的国家药典委员会于2017年6月在网上公示了达肝素钠、依诺肝素钠、那屈肝素钙3类低分子肝素标准征求意见稿,作为2020年版《中国药典》拟新增品种,为保证标准的顺利实施,急需建立首批低分子肝素相对分子质量国家对照品及相对分子质量...目的国家药典委员会于2017年6月在网上公示了达肝素钠、依诺肝素钠、那屈肝素钙3类低分子肝素标准征求意见稿,作为2020年版《中国药典》拟新增品种,为保证标准的顺利实施,急需建立首批低分子肝素相对分子质量国家对照品及相对分子质量系统适用性对照品。方法以WHO第2次低分子肝素相对分子质量测定用对照品(2nd international standard low molecular weight heparin for molecular weight calibration,批号05/112)为低分子肝素相对分子质量对照品,采用公示标准中“相对分子质量与相对分子质量分布”检查法,对低分子肝素相对分子质量国家对照品待标品(批号:140820-201801)、达肝素钠国家对照品待标品(批号:140811-201801)、依诺肝素钠国家对照品待标品(批号:140810-201801)、那屈肝素钙国家对照品待标品(批号:140812-201801)进行相对分子质量与相对分子质量分布测定,由全国13个药检所及低分子肝素生产厂家实验室协作标定。结果对低分子肝素相对分子质量国家对照品待标品相对分子质量600~18000的18个点百分面积进行标定,对实验室内误差进行考察,13个实验室中有2个实验室(7号、9号)部分点的标准差(standard deviation,SD)为1%~2%,其余11个实验室的SD值均小于1%。对实验室间误差进行考察,18个数据点的SD值均小于1%,相对标准偏差(RSD)除小分子部分的两个点均小于5%。对达肝素钠、依诺肝素钠、那屈肝素钙国家对照品待标品重均相对分子质量进行标定,实验室内SD值为4~110,RSD小于2.5%,实验室间SD值小于30,RSD小于1%。结论经国家药品标准物质委员会审定后批准,低分子肝素相对分子质量国家对照品待标品(批号:140820-201801),附带宽分布标样表;达肝素钠国家对照品待标品(批号:140811-201801),重均相对分子质量6268;依诺肝素钠国家对照品待标品(批号:140810-201801),重均相对分子质量4435;那屈肝素钙国家对照品待标品(批号:140812-201801),重均相对分子质量4832,可以用于低分子肝素相对分子质量与相对分子质量分布检查使用。展开更多
目的:建立核磁共振一维碳谱定性鉴别低分子肝素类型的方法。方法:一维13C-NMR实验在装配5 mm BBO探头的Bruker Ascend-500核磁共振谱仪上采集。采样时间1.1s;弛豫时间1s;测量温度40℃;谱宽δ(ppm)236。结果:比较不同类型低分子量肝素标...目的:建立核磁共振一维碳谱定性鉴别低分子肝素类型的方法。方法:一维13C-NMR实验在装配5 mm BBO探头的Bruker Ascend-500核磁共振谱仪上采集。采样时间1.1s;弛豫时间1s;测量温度40℃;谱宽δ(ppm)236。结果:比较不同类型低分子量肝素标准品的碳谱精细结构信息发现,不同类型的低分子量肝素都有其特征的碳谱信号,因此可以通过碳谱特征信号对低分子量肝素进行区分。结论:核磁共振一维碳谱定性鉴别低分子肝素的方法专属性强,简单方便,是鉴别低分子量肝素较好的方法。展开更多
文摘This study was intended to investigate into the incidence rates of deep vein thrombosis (DVT) in patients who used prophylactic antithrombotic medications after total knee arthroplasty (TKA), and to compare clinical results in groups treated with Rivaroxaban versus Dalteparin sodium as prophylactic antithrombotic medications. This prospective study was performed in 300 patients who underwent TKA between November 2011 and December 2012. The prophylactic therapy was given to 150 patients in Rivaroxaban group and Dalteparin sodium group, respectively. In addition, intermittent compression pump and stocking were used in all the groups immediately after TKA. In order to determine the incidence of DVT, color Doppler ultrasonography, D-dimer, and clinical symptom examination were conducted. There were 17 cases (11.3%) of DVT in Rivaroxaban group and 18 cases (12.0%) of DVT in Dalteparin sodium group after TKA, and no significant difference was seen between both groups. Between patients with DVT and those without DVT after TKA at 4 days in both groups, there was a significant difference in the swelling indices. Moreover, a significant difference was observed in the evaluation of bruise. The early signs of DVT after TKA are unknown, however, some initial clinical signs such as swelling have been observed. After using the said prophylactic drugs, the lower incidence of DVT was seen, and there was no difference between the types of drugs. Pharmacological therapy (either Rivaroxaban or Dalteparin sodium) after TKA is considered effective for DVT prevention. There is also a need to consider constant monitoring of clinical symptoms.
文摘Objective To prospectively evaluate the safety and therapeutic efficacy ofdalteparin in patients with high risk non-ST- elevation acute coronary syndromes （ACS） during percutaneous coronary intervention （PCI）. Methods A total of 175 patients with high risk non-ST-elevation ACS were randomly assigned to 2 groups [dalteparin group and unfractionated heparin （UFH） group]. The patients in dalteparin group were given dalteparin at a dose of 5,000U subcutaneously soon after diagnosis and then an additional 60U/ kg intravenous bolus ofdalteparin before emergent PCI. Vascular access sheaths were removed immediately after PCI or coronary artery angiography; the patients in UFH group were given UFH intravenously at a dose of 25mg just before PCI and an additional 65mg bolus was administered if angiographic findings showed that the patients were suitable for percutaneous transluminal coronary angioplasty （PTCA）. Sheaths were removed at 4-6 hours after PCI; Results Eighty-three patients in dalteparin group underwent PCI while 82 patients in UFH group underwent PCI; anti-Xa activities of 52 patients in daltepafin group were measured. The average anti-Xa activity was （0. 83± 0.26） U/ml at 15 minutes after intravenous injection of dalteparin and anti-Xa〉0.SU/ml was obtained in 96.1% of the patients; hematomas at puncture sites were significantly fewer in dalteparin group as compared with UFH group （2.3% vs 9.2%, P 〈 0.05）; none of the patients in 2 groups suffered major bleeding events. No death, acute arterial reocclusion or emergent revascularization events occurred at 30 days after PCI. Conclusions Our study demonstrated that early subcutaneous injection ofdalteparin at a dose 5,000U after diagnosis and an additional 60U/kg intravenous bolus ofdalteparin before PCI is safe and efficacious for patients with high risk non-ST-elevation ACS undergoing emergent PCI.
文摘Objective:To investigate the therapeutic effect of trans-tarsal sinus approach surgery combined with dalteparin sodium and furosemide in the treatment of heel bone fracture.Methods:A hundred patients with heel bone fracture who were hospitalized from August 2023 to January 2025 were selected and randomly divided into two groups of 50 cases each.The control group was operated by purely trans-tarsal sinus approach,and the observation group added dalteparin sodium and furosemide on this basis.Postoperative limb swelling,pain,coagulation and inflammation indexes,fracture healing time,foot function and complications were compared between the two groups.Results:In the observation group,postoperative limb swelling subsided faster,pain score was lower,coagulation and inflammation indexes improved more significantly,fracture healing time was shorter,foot function recovery was better,and complication rate was lower,P<0.05.Conclusion:The treatment of heel fracture by trans-tarsal sinus approach combined with sodium heparin and furosemide can significantly accelerate the patient’s recovery and reduce the occurrence of complications,which has high clinical application value.
文摘目的国家药典委员会于2017年6月在网上公示了达肝素钠、依诺肝素钠、那屈肝素钙3类低分子肝素标准征求意见稿,作为2020年版《中国药典》拟新增品种,为保证标准的顺利实施,急需建立首批低分子肝素相对分子质量国家对照品及相对分子质量系统适用性对照品。方法以WHO第2次低分子肝素相对分子质量测定用对照品(2nd international standard low molecular weight heparin for molecular weight calibration,批号05/112)为低分子肝素相对分子质量对照品,采用公示标准中“相对分子质量与相对分子质量分布”检查法,对低分子肝素相对分子质量国家对照品待标品(批号:140820-201801)、达肝素钠国家对照品待标品(批号:140811-201801)、依诺肝素钠国家对照品待标品(批号:140810-201801)、那屈肝素钙国家对照品待标品(批号:140812-201801)进行相对分子质量与相对分子质量分布测定,由全国13个药检所及低分子肝素生产厂家实验室协作标定。结果对低分子肝素相对分子质量国家对照品待标品相对分子质量600~18000的18个点百分面积进行标定,对实验室内误差进行考察,13个实验室中有2个实验室(7号、9号)部分点的标准差(standard deviation,SD)为1%~2%,其余11个实验室的SD值均小于1%。对实验室间误差进行考察,18个数据点的SD值均小于1%,相对标准偏差(RSD)除小分子部分的两个点均小于5%。对达肝素钠、依诺肝素钠、那屈肝素钙国家对照品待标品重均相对分子质量进行标定,实验室内SD值为4~110,RSD小于2.5%,实验室间SD值小于30,RSD小于1%。结论经国家药品标准物质委员会审定后批准,低分子肝素相对分子质量国家对照品待标品(批号:140820-201801),附带宽分布标样表;达肝素钠国家对照品待标品(批号:140811-201801),重均相对分子质量6268;依诺肝素钠国家对照品待标品(批号:140810-201801),重均相对分子质量4435;那屈肝素钙国家对照品待标品(批号:140812-201801),重均相对分子质量4832,可以用于低分子肝素相对分子质量与相对分子质量分布检查使用。
文摘目的:建立核磁共振一维碳谱定性鉴别低分子肝素类型的方法。方法:一维13C-NMR实验在装配5 mm BBO探头的Bruker Ascend-500核磁共振谱仪上采集。采样时间1.1s;弛豫时间1s;测量温度40℃;谱宽δ(ppm)236。结果:比较不同类型低分子量肝素标准品的碳谱精细结构信息发现,不同类型的低分子量肝素都有其特征的碳谱信号,因此可以通过碳谱特征信号对低分子量肝素进行区分。结论:核磁共振一维碳谱定性鉴别低分子肝素的方法专属性强,简单方便,是鉴别低分子量肝素较好的方法。
